J. Safra Sarasin Holding 13F: Cuts JNJ Stake by $11M
Key Points
- J. Safra Sarasin Holding reduced its holdings in Johnson & Johnson by 42,490 shares, a 9.3% decrease, in a filing on October 26, 2026.
- As of October 26, the stock closed at $266.30, while it traded recently around $266.35, about equal to its closing price.
- The firm now holds 414,478 shares, which make up 4.36% of its total reported value of $2.37 billion.
Get Johnson & Johnson text alerts
We text you when insiders, Congress, analysts or big funds move on $JNJ.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Johnson & Johnson alert may contain errors. Disclosures
On October 26, 2026, J. Safra Sarasin Holding trimmed its stake in Johnson & Johnson (JNJ) by 42,490 shares, bringing its total to 414,478 shares valued at approximately $103.5 million. This information comes from the fund's latest Form 13F filing with the SEC.
J. Safra Sarasin's reduction in shares represents a 9.3% decrease in its position. The total reported value of the fund's investment in Johnson & Johnson now stands at about $103.5 million, which is 4.36% of its overall portfolio of $2.37 billion.
JNJ
Johnson & Johnson
Where Johnson & Johnson Fits in J. Safra Sarasin's Portfolio
J. Safra Sarasin's stake in Johnson & Johnson ranks fourth among its 800 reported positions. The reduction in shares reflects a strategic adjustment in the fund's portfolio, which has seen an estimated gain of about 3.1% compared to the average cost of its holdings.
Other Institutional Activity in Johnson & Johnson
Signaturefd grew its holdings in Johnson & Johnson by 4,917 shares, ending with 77,490 shares worth about $20.5 million. Meanwhile, Ag2R la Mondiale Gestion D'Actifs trimmed its stake by 13,849 shares, bringing its total to 128,512 shares valued at approximately $34.0 million. State Farm Mutual Automobile Insurance Co maintained its position with 31,590,952 shares worth about $8.41 billion.
Johnson & Johnson Stock Up 1.0%
As of October 26, Johnson & Johnson shares closed at $266.30. Recently, they traded around $266.35, which is about equal to the closing price. The stock is currently above its 50-day moving average of $265.20 and its 200-day average of $245.47, indicating some strength in its price action.
Recent Earnings
Johnson & Johnson reported trailing twelve-month revenue of approximately $99.3 billion with an earnings per share (EPS) of $6.59. The next earnings report is scheduled for January 26, 2027.
Dividend
Johnson & Johnson pays an annual dividend rate of $5.36 per share, yielding about 2.03%. The dividend payout ratio stands at 80.1%.
Insider Buying and Selling at Johnson & Johnson
Several insiders sold shares earlier this year. Elizabeth Forminard, an officer, sold 15,918 shares on August 6, while CEO Joaquin Boix Duato sold 123,291 shares on August 13. Jennifer L. Taubert sold 15,000 shares on August 17, and Timothy Schmid sold 33,597 shares on September 2.
Analysts Set New Price Targets
On October 14, 2026, Leerink Partners maintained its rating of Outperform with a price target of $272. Wells Fargo also maintained its Overweight rating with a target of $275. RBC Capital kept its Outperform rating with a target of $280, while Morgan Stanley maintained an Overweight rating with a target of $292.
About Johnson & Johnson
Johnson & Johnson is a global healthcare company that develops, manufactures, and sells a wide range of products. It operates mainly in two segments: Innovative Medicine and MedTech, focusing on advancing health and wellness worldwide.
Bottom Line
Investors will be watching for Johnson & Johnson's upcoming earnings report on January 26, 2027, as well as any further institutional activity following this recent filing. J. Safra Sarasin's position change suggests ongoing adjustments in its investment strategy amidst a stable trading environment for JNJ.
Related Filing Alerts
Source: J. Safra Sarasin Holding's 13F filing on $JNJ (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts